The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala HM, Hogan K, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan DM, Landgren O, Grant S. Clin Cancer Res. 2015 Oct 7. pii: clincanres.1076.2015. [Epub ahead of print] PMID: 26446942 [PubMed - as supplied by publisher] READ MORE

Posted: November 19, 2015

Potential role of FLT3-ligand in the angiogenic process of multiple myeloma.

Kokonozaki M, Tsirakis G, Devetzoglou M, Kyriakaki S, Antonakis A, Vyzoukaki R, Pappa CA, Tzardi M, Alexandrakis MG. Leuk Res. 2015 Oct 20. pii: S0145-2126(15)30534-8. doi: 10.1016/j.leukres.2015.10.009. [Epub ahead of print] PMID: 26521986 [PubMed - as supplied by publisher] READ MORE

Posted: November 19, 2015

The Proteasome Inhibitor, Bortezomib, Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.

Toscani D, Palumbo C, Dalla Palma B, Ferretti M, Bolzoni M, Marchica V, Sena P, Martella E, Mancini C, Ferri V, Costa F, Accardi F, Craviotto L, Aversa F, Giuliani N. J Bone Miner Res. 2015 Nov 9. doi: 10.1002/jbmr.2741. [Epub ahead of print] PMID: 26551485 [PubMed - as supplied by publisher] READ MORE

Posted: November 19, 2015

Page 40 of 87« First...102030...3839404142...506070...Last »